NBJ
Microscope with slide

Nutrigenomics faces scrutiny from feds

Quantified diagnostics thrill consumers. FDA, not so much.

When personal gene tests first started rolling out to the general public, the cost was in the thousands. Early adopters helped bring the price down to the hundreds, then a cool C-note. The promise of learning your personal genetic history was fascinating. Even more tantalizing was using the genetic information as a diagnostic tool to help you plan for—and even prevent—a disease, a kind of road map for hazards ahead.

All access premium subscription

This content requires a subscription to Nutrition Business Journal.

As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.

Email [email protected] for more information about subscribing.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish